Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.

Ilan ShimonZaina AdnanAlexander GorshteinLior BarafNariman Saba KhazenMichal GershinskyYulia PaukerAli AbidMark J NivenCarmela ShechnerYona Greenman

Published in: Endocrine (2018)

In the real-life scenario ~54% of patients with acromegaly resistant to first-generation SSA, may normalize IGF-1 with pasireotide; however, 63% experienced glucose control deterioration.

Keyphrases

growth hormone
pi k akt
type diabetes
adipose tissue
neuroendocrine tumors
cell proliferation
signaling pathway